BioPharma Dive November 16, 2022
The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.
With midterm elections resulting in a divided Congress, the U.S. Department of Health and Human Services will be free to focus on longstanding priorities for the agency, such as implementing drug negotiation policy within Medicare, its top official said.
“In a way, we’re now going to be able to concentrate on the work we have to still execute on,” HHS Secretary Xavier Becerra said at the HLTH conference in Las Vegas on Tuesday.
Under the Inflation Reduction Act passed earlier this year, Congress granted Medicare the power to negotiate how much it pays for certain prescription drugs starting in 2026, and...
Today's Sponsors
Today's Sponsor